Study of SC101 Injection Into Perirenal Fat to Treat Resistant Hypertension in Adults With Moderate to Severe Chronic Kidney Disease

What this Trial Is About

Researchers are evaluating the safety and effectiveness of a new treatment called SC101 for adults aged 18 to 65 who have resistant hypertension and moderate to severe chronic kidney disease CKD. This early-phase, open-label study explores a single injection of SC101, a small interfering RNA siRNA agent, into the perirenal fat, aiming to understand its impact on blood pressure and kidney function. Participants will receive one single-session injection of SC101 into the bilateral perirenal fat guided by ultrasound. The study focuses on the safety of this local injection procedure and measures its initial and lasting effects on blood pressure. The trial also investigates the biological mechanism involving the perirenal fat and nerve connection and explores how the treatment might affect kidney health. During the study, participants will be monitored for adverse events from the day of injection through one year. Blood pressure will be measured at baseline and multiple follow-up visits over six months, including 24-hour ambulatory and office readings. Researchers will also track changes in antihypertensive medication use and monitor kidney function and procedure-related safety. The total follow-up period lasts 364 days after treatment.

Safety and Efficacy of SC101 Via Perirenal Fat Injection for Resistant Hypertension in Patients With Moderate to Severe Chronic Kidney Disease